198 related articles for article (PubMed ID: 34967586)
1. Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes.
Hattakitpanitchakul S; Kobbuaklee S; Wudhikarn K; Polprasert C
Asian Pac J Cancer Prev; 2021 Dec; 22(12):4037-4042. PubMed ID: 34967586
[TBL] [Abstract][Full Text] [Related]
2. Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study.
Buccisano F; Piccioni AL; Nobile C; Criscuolo M; Niscola P; Tatarelli C; Fianchi L; Villivà N; Neri B; Carmosino I; Gumenyuk S; Mancini S; Voso MT; Maurillo L; Breccia M; Zini G; Venditti A; Fenu S; Spiriti MA; Latagliata R;
Ann Hematol; 2016 Jun; 95(7):1059-65. PubMed ID: 27091349
[TBL] [Abstract][Full Text] [Related]
3. Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents.
Castelli R; Schiavon R; Rossi V; Deliliers GL
Med Oncol; 2018 Apr; 35(5):76. PubMed ID: 29675620
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion.
Park S; Kelaidi C; Meunier M; Casadevall N; Gerds AT; Platzbecker U
Ann Hematol; 2020 Jan; 99(1):7-19. PubMed ID: 31650290
[TBL] [Abstract][Full Text] [Related]
5. A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry.
Houston BL; Jayakar J; Wells RA; Lenis M; Zhang L; Zhu N; Leitch HA; Nevill TJ; Yee KWL; Leber B; Sabloff M; St-Hilaire E; Kumar R; Geddes M; Shamy A; Storring JM; Keating MM; Elemary M; Delage R; Mamedov A; Buckstein R
Ann Hematol; 2017 Dec; 96(12):2025-2029. PubMed ID: 28975386
[TBL] [Abstract][Full Text] [Related]
6. Distribution of serum erythropoietin levels in Japanese patients with myelodysplastic syndromes.
Suzuki T; Oh I; Ohmine K; Meguro A; Mori M; Fujiwara S; Yamamoto C; Nagai T; Ozawa K
Int J Hematol; 2015 Jan; 101(1):32-6. PubMed ID: 25374009
[TBL] [Abstract][Full Text] [Related]
7. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Park S; Hamel JF; Toma A; Kelaidi C; Thépot S; Campelo MD; Santini V; Sekeres MA; Balleari E; Kaivers J; Sapena R; Götze K; Müller-Thomas C; Beyne-Rauzy O; Stamatoullas A; Kotsianidis I; Komrokji R; Steensma DP; Fensterl J; Roboz GJ; Bernal T; Ramos F; Calabuig M; Guerci-Bresler A; Bordessoule D; Cony-Makhoul P; Cheze S; Wattel E; Rose C; Vey N; Gioia D; Ferrero D; Gaidano G; Cametti G; Pane F; Sanna A; Germing U; Sanz GF; Dreyfus F; Fenaux P
J Clin Oncol; 2017 May; 35(14):1591-1597. PubMed ID: 28350519
[TBL] [Abstract][Full Text] [Related]
8. High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM.
Kelaidi C; Beyne-Rauzy O; Braun T; Sapena R; Cougoul P; Adès L; Pillard F; Lamberto C; Charniot JC; Guerci A; Choufi B; Stamatoullas A; Slama B; De Renzis B; Ame S; Damaj G; Boyer F; Chaury MP; Legros L; Cheze S; Testu A; Gyan E; Béné MC; Rose C; Dreyfus F; Fenaux P
Ann Hematol; 2013 May; 92(5):621-31. PubMed ID: 23358617
[TBL] [Abstract][Full Text] [Related]
9. Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.
Park S; Kosmider O; Maloisel F; Drenou B; Chapuis N; Lefebvre T; Karim Z; Puy H; Alary AS; Ducamp S; Verdier F; Bouilloux C; Rousseau A; Jacob MC; Debliquis A; Charpentier A; Gyan E; Anglaret B; Leyronnas C; Corm S; Slama B; Cheze S; Laribi K; Amé S; Rose C; Lachenal F; Toma A; Pica GM; Carre M; Garban F; Mariette C; Cahn JY; Meunier M; Herault O; Fenaux P; Wagner-Ballon O; Bardet V; Dreyfus F; Fontenay M
Haematologica; 2019 Mar; 104(3):497-504. PubMed ID: 30287621
[TBL] [Abstract][Full Text] [Related]
10. Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes.
Caballero JC; Dávila J; López-Pavía M; Such E; Bernal T; Ramos F; Calabuig M; Hernández Sánchez JM; Pomares H; Sánchez Barba M; Abáigar M; González B; Merchán B; Sancho-Tello R; Callejas M; Muñoz-Novas C; Cerveró C; Sanz G; Hernández Rivas JM; Díez Campelo M
Ther Adv Hematol; 2024; 15():20406207231218157. PubMed ID: 38186638
[TBL] [Abstract][Full Text] [Related]
11. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.
Toma A; Kosmider O; Chevret S; Delaunay J; Stamatoullas A; Rose C; Beyne-Rauzy O; Banos A; Guerci-Bresler A; Wickenhauser S; Caillot D; Laribi K; De Renzis B; Bordessoule D; Gardin C; Slama B; Sanhes L; Gruson B; Cony-Makhoul P; Chouffi B; Salanoubat C; Benramdane R; Legros L; Wattel E; Tertian G; Bouabdallah K; Guilhot F; Taksin AL; Cheze S; Maloum K; Nimuboma S; Soussain C; Isnard F; Gyan E; Petit R; Lejeune J; Sardnal V; Renneville A; Preudhomme C; Fontenay M; Fenaux P; Dreyfus F
Leukemia; 2016 Apr; 30(4):897-905. PubMed ID: 26500139
[TBL] [Abstract][Full Text] [Related]
13. Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes.
Wallvik J; Stenke L; Bernell P; Nordahl G; Hippe E; Hast R
Eur J Haematol; 2002 Mar; 68(3):180-5. PubMed ID: 12068800
[TBL] [Abstract][Full Text] [Related]
14. Distribution of serum erythropoietin levels in lower risk myelodysplastic syndrome cases with anemia.
Nakazaki K; Nannya Y; Kurokawa M
Int J Hematol; 2014 Jan; 99(1):53-6. PubMed ID: 24307517
[TBL] [Abstract][Full Text] [Related]
15. Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response.
Villegas A; Arrizabalaga B; Fernández-Lago C; Castro M; Mayans JR; González-Porras JR; Duarte RF; Remacha AF; Luño E; Gasquet JA
Curr Med Res Opin; 2011 May; 27(5):951-60. PubMed ID: 21381892
[TBL] [Abstract][Full Text] [Related]
16. ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial.
Morita Y; Nannya Y; Ichikawa M; Hanamoto H; Shibayama H; Maeda Y; Hata T; Miyamoto T; Kawabata H; Takeuchi K; Tanaka H; Kishimoto J; Miyano S; Matsumura I; Ogawa S; Akashi K; Kanakura Y; Mitani K
Int J Hematol; 2022 Nov; 116(5):659-668. PubMed ID: 35821550
[TBL] [Abstract][Full Text] [Related]
17. Stanozolol for the treatment of anemic lower-risk myelodysplastic syndromes without del(5q) after failure of epoetin alfa: findings from a retrospective study.
Qu WY; Zhao L; Tan XC; Zhao YH
Ann Hematol; 2021 Jun; 100(6):1451-1457. PubMed ID: 33837816
[TBL] [Abstract][Full Text] [Related]
18. The fraction of CD117/c-KIT-expressing erythroid precursors predicts ESA response in low-risk myelodysplastic syndromes.
Raimbault A; Itzykson R; Willems L; Rousseau A; Chapuis N; Mathis S; Clauser S; Radford-Weiss I; Bouscary D; Fontenay M; Kosmider O; Bardet V
Cytometry B Clin Cytom; 2019 May; 96(3):215-222. PubMed ID: 30963682
[TBL] [Abstract][Full Text] [Related]
19. Mutations and karyotype predict treatment response in myelodysplastic syndromes.
Idossa D; Lasho TL; Finke CM; Ketterling RP; Patnaik MM; Pardanani A; Gangat N; Tefferi A
Am J Hematol; 2018 Nov; 93(11):1420-1426. PubMed ID: 30152885
[TBL] [Abstract][Full Text] [Related]
20. Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes.
Santini V
Oncologist; 2011; 16 Suppl 3():35-42. PubMed ID: 21930833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
